These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 26700070)

  • 21. Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology.
    Rojo LE; Gaspar PA; Silva H; Risco L; Arena P; Cubillos-Robles K; Jara B
    Pharmacol Res; 2015 Nov; 101():74-85. PubMed ID: 26218604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain.
    Ellinger LK; Ipema HJ; Stachnik JM
    Ann Pharmacother; 2010 Apr; 44(4):668-79. PubMed ID: 20233913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antipsychotic induced weight gain in schizophrenia:mechanisms and management.
    Rege S
    Aust N Z J Psychiatry; 2008 May; 42(5):369-81. PubMed ID: 18473255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Metabolic risk during antipsychotic treatment in patients with schizophrenia].
    Rzewuska M
    Psychiatr Pol; 2007; 41(4):457-72. PubMed ID: 18046977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).
    Bond DJ; Kauer-Sant'Anna M; Lam RW; Yatham LN
    J Affect Disord; 2010 Jul; 124(1-2):108-17. PubMed ID: 19914720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenetics of antipsychotic-induced weight gain.
    Correll CU; Malhotra AK
    Psychopharmacology (Berl); 2004 Aug; 174(4):477-89. PubMed ID: 15243737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications.
    Faulkner G; Cohn TA
    Can J Psychiatry; 2006 Jul; 51(8):502-11. PubMed ID: 16933587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 'Why getting fat, Doc?' Weight gain and psychotropic medications.
    Malhi GS; Mitchell PB; Caterson I
    Aust N Z J Psychiatry; 2001 Jun; 35(3):315-21. PubMed ID: 11437804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interaction between weight and medications in psychological illnesses of children.
    Apter A; Steingart L
    World Rev Nutr Diet; 2013; 106():174-80. PubMed ID: 23428698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Atypical antipsychotic induced weight gain and metabolic disorders].
    Rojas G P; Poblete A C; Orellana G X; Rouliez A K; Liberman G C
    Rev Med Chil; 2009 Jan; 137(1):106-14. PubMed ID: 19399331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antipsychotic-induced weight gain: a review of the literature.
    Allison DB; Casey DE
    J Clin Psychiatry; 2001; 62 Suppl 7():22-31. PubMed ID: 11346192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. When essential medications provoke new health problems: the metabolic effects of second-generation antipsychotics.
    Stein K
    J Am Diet Assoc; 2010 Jul; 110(7):992-1001. PubMed ID: 20630154
    [No Abstract]   [Full Text] [Related]  

  • 33. The effect of antidepressants and antipsychotics on weight gain in children and adolescents.
    Reekie J; Hosking SP; Prakash C; Kao KT; Juonala M; Sabin MA
    Obes Rev; 2015 Jul; 16(7):566-80. PubMed ID: 26016407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of antipsychotic medications on appetite, weight, and insulin resistance.
    Deng C
    Endocrinol Metab Clin North Am; 2013 Sep; 42(3):545-63. PubMed ID: 24011886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic risk during antipsychotic treatment.
    Newcomer JW
    Clin Ther; 2004 Dec; 26(12):1936-46. PubMed ID: 15823759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tiliroside, a glycosidic flavonoid, ameliorates obesity-induced metabolic disorders via activation of adiponectin signaling followed by enhancement of fatty acid oxidation in liver and skeletal muscle in obese-diabetic mice.
    Goto T; Teraminami A; Lee JY; Ohyama K; Funakoshi K; Kim YI; Hirai S; Uemura T; Yu R; Takahashi N; Kawada T
    J Nutr Biochem; 2012 Jul; 23(7):768-76. PubMed ID: 21889885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects.
    Coccurello R; Caprioli A; Ghirardi O; Conti R; Ciani B; Daniele S; Bartolomucci A; Moles A
    Psychopharmacology (Berl); 2006 Jul; 186(4):561-71. PubMed ID: 16758241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of weight gain induced by antipsychotic drugs.
    Baptista T
    J Clin Psychiatry; 2002 Mar; 63(3):245-6. PubMed ID: 11926725
    [No Abstract]   [Full Text] [Related]  

  • 39. Antidiabetic medications and weight gain: implications for the practicing physician.
    McFarlane SI
    Curr Diab Rep; 2009 Jun; 9(3):249-54. PubMed ID: 19490828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of schizophrenia with obesity, metabolic, and endocrinological disorders.
    Monteleone P; Martiadis V; Maj M
    Psychiatr Clin North Am; 2009 Dec; 32(4):775-94. PubMed ID: 19944883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.